Afișare rezultate
Afisarea articolelor 21-1(1) pentru cuvîntul-cheie "
Romiplostim"
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia |
Robak Tadeusz12, Kazmierczak Maciej3, Jarque Isidro45, Musteaţă Vasile6, Trelinski Jacek12, Cooper Nichola7, Kiessling Peter C.8, Massow Ute8, Woltering Franz8, Snipes Rose G.9, Ke Juan10, Langdon Grant11, Bussel James Bruce12, Jolles Stephen13 |
1 Medical University of Lodz, 2 Copernicus Memorial Hospital, Lodz, 4 La Fe University and Polytechnic Hospital, Valencia, 6 Institute of Oncology, 7 Imperial College Healthcare National Health Service Trust, London, 8 Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein, 9 UCB Pharma, Raleigh, 11 PTx Solutions Ltd., London, 12 Weill Cornell Medicine, New York, 13 University Hospital of Wales, Cardiff |
Blood Advances |
Nr. 4(17) / 2020 / ISSN 2473-9537 |
Disponibil online 15 March, 2021. Descarcări-0. Vizualizări-485 |
-----------------------------------------------------------------------------------------------------------------------------------
21-1 of 1